Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in February 1999, BioVex is a private biotechnology company that is developing a new class of potent
vaccines principally to treat and prevent cancer. The company has three technology platforms based on the
manipulation of the Herpes simplex type 1 virus. BioVex has two vaccine platforms: OncoVEX and ImmunoVEX, plus
NeuroVEX, a functional genomics platform for gene determination in the nervous system.
BioVex is using its vector technology to deliver genes to dendritic cells to screen for the induction of an immune
response against tumours and infectious disease. This allows partner companies to assess genes identified as having
immunotherapeutic potential.